Not a single study
Story checked
Long-Term Ritlecitinib Effects Vary by Hair Loss Extent (opens in a new tab)
medscape.com · 2026-10-06
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Long-Term Ritlecitinib Effects Vary by Hair Loss Extent
medscape.com · 2026-10-06
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedIn a new analysis of the phase 3 ALLEGRO-LT study, people with the least scalp hair loss at baseline had the greatest and fastest response to ritlecitinib.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedA Severity of Alopecia Tool (SALT) score of 20 or less was achieved at 6 months by 76.3% of patients who initially had 25% to less than 50% scalp hair loss, 61.2% of those with 50% to less than 95% hair loss, and 22.5% of those with 95% to 100% hair loss.View evidenceHide evidence
As stated76.3%, 61.2%, and 22.5% at 6 months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedAt 12 months, 86.4%, 72.9%, and 34% of patients in the three baseline severity groups achieved SALT 20 or less, and the results plateaued toward the 5-year follow-up, where 85.6%, 79.1%, and 37.5% had met the target.View evidenceHide evidence
As stated86.4%, 72.9%, 34% at 12 months; 85.6%, 79.1%, 37.5% at 5 years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe analysis only considered newly enrolled patients with at least 25% scalp hair loss who had not previously received ritlecitinib, and it was a post hoc analysis using last observation carried forward data.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedAt 5 years, the story reports no venous thromboembolism and low rates of herpes zoster, serious infection, and major adverse cardiovascular events in the de novo cohort.View evidenceHide evidence
As statedno VTE; zoster 1.8%, serious infection 1.3%, MACE 0.9%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study.
Dermatology and Therapy · 2026 · PubMed, Europe PMC
ISID0598 - Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
2023 · Crossref
Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
American Journal of Clinical Dermatology · 2026 · PubMed, Europe PMC
ISIDLB1697 - Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study
2023 · Crossref
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
American Journal of Clinical Dermatology · 2026 · PubMed, Europe PMC
And 10 more candidates considered.